Dermapharm Holding Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Hans-Georg Feldmeier

Chief executive officer

€1.4m

Total compensation

CEO salary percentage59.7%
CEO tenure7.3yrs
CEO ownershipn/a
Management average tenure2.2yrs
Board average tenure7.3yrs

Recent management updates

It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope

Jun 21
It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope

Recent updates

Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden

Sep 28
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden

Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next

Aug 31
Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next

Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable

Aug 17
Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable

It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope

Jun 21
It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope

These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively

Apr 29
These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively

Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings

Feb 07
Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings

Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly

Dec 15
Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued

Nov 17
An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued

Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet

Aug 28
Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet

Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price

Aug 01
Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price

Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet

May 29
Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet

Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?

May 03
Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?

Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear

Apr 04
Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear

We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt

Feb 22
We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt

Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Nov 17
Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Aug 16
Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Is Dermapharm Holding (ETR:DMP) A Risky Investment?

May 18
Is Dermapharm Holding (ETR:DMP) A Risky Investment?

Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?

Feb 17
Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?

These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well

Nov 19
These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well

Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?

Aug 21
Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?

Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?

Jul 31
Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?

Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?

May 03
Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?

Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)

Apr 16
Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)

Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly

Mar 25
Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly

Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?

Mar 07
Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?

Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?

Feb 15
Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?

Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend

Jan 29
Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend

Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?

Dec 24
Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?

The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More

Dec 07
The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More

Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models

Nov 18
Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models

CEO Compensation Analysis

How has Hans-Georg Feldmeier's remuneration changed compared to Dermapharm Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

€91m

Jun 30 2024n/an/a

€83m

Mar 31 2024n/an/a

€57m

Dec 31 2023€1m€821k

€62m

Sep 30 2023n/an/a

€95m

Jun 30 2023n/an/a

€123m

Mar 31 2023n/an/a

€146m

Dec 31 2022€1m€800k

€134m

Sep 30 2022n/an/a

€176m

Jun 30 2022n/an/a

€185m

Mar 31 2022n/an/a

€211m

Dec 31 2021€1m€800k

€210m

Sep 30 2021n/an/a

€162m

Jun 30 2021n/an/a

€123m

Mar 31 2021n/an/a

€95m

Dec 31 2020€736k€411k

€86m

Compensation vs Market: Hans-Georg's total compensation ($USD1.44M) is about average for companies of similar size in the German market ($USD1.63M).

Compensation vs Earnings: Hans-Georg's compensation has been consistent with company performance over the past year.


CEO

Hans-Georg Feldmeier

7.3yrs

Tenure

€1,375,000

Compensation

Dr. Hans-Georg Feldmeier is the Chief Executive Officer and Chairman of the Management Board at Dermapharm Holding SE and also serves as Member of the Management Board from August 2017.


Leadership Team

NamePositionTenureCompensationOwnership
Hans-Georg Feldmeier
CEO & Chairman of the Management Board7.3yrs€1.38mno data
Christof Dreibholz
CFO, Chief Compliance Officer & Member of Management Board2yrs€617.00kno data
Andreas Eberhorn
Chief Marketing Officer & Member of Management Board2.2yrs€612.00kno data
Britta Hamberger
Head of Investor Relations & Corporate Communicationsno datano datano data

2.2yrs

Average Tenure

Experienced Management: DMP's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lothar Lanz
Independent Member of Supervisory Board6.8yrs€80.00kno data
Wilhelm Beier
Chairman of the Supervisory Board7.3yrs€80.00kno data
Erwin Kern
Independent Vice Chairman of the Supervisory Board7.3yrs€80.00kno data

7.3yrs

Average Tenure

68yo

Average Age

Experienced Board: DMP's board of directors are considered experienced (7.3 years average tenure).